Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1508 ARTÍCULOS , VIENDO DEL 226 AL 240

Does the Interplay Between Aging and Neuroinflammation Modulate Alzheimer's Disease Clinical Phenotypes? A Clinico-Pathological Perspective

Taipa R, Sousa AL, Melo Pires M, Sousa N.

J Alzheimers Dis. 2016 May 11;53(2):403-17. doi: 10.3233/JAD-160121.

Reproducibility of hippocampal atrophy rates measured with manual, FreeSurfer, AdaBoost, FSL/FIRST and the MAPS-HBSI methods in Alzheimer's disease

Cover KS, van Schijndel RA, Versteeg A, Leung KK, Mulder ER, Jong RA, Visser PJ, Redolfi A, Revillard J, Grenier B, Manset D, Damangir S, Bosco P, Vrenken H, van Dijk BW, Frisoni GB, Barkhof F; Alzheimer's Disease Neuroimaging Initiative, neuGRID.

Psychiatry Res Neuroimaging. 2016 Jun 30;252:26-35. doi: 10.1016/j.pscychresns.2016.04.006. Epub 2016 May 11.

Induced pluripotent stem cells in Alzheimer's disease: applications for disease modeling and cell-replacement therapy

Yang J, Li S, He XB, Cheng C, Le W.

Mol Neurodegener. 2016 May 17;11(1):39. doi: 10.1186/s13024-016-0106-3.

Amyloid beta directed antibody for Alzheimer's disease, an evidence based meta-analysis

Li C, Ma Q, Chen S, Feng J, He Y.

Cell Mol Biol (Noisy-le-grand). 2016 Apr 30;62(4):83-7.

Targeting New Pharmacological Approaches for Alzheimer's Disease: Potential for Statins and Phosphodiesterase Inhibitors

Sallustio F, Studer V.

CNS Neurol Disord Drug Targets. 2016;15(6):647-59. doi: 10.2174/1871527315666160518123727.

Insulin and the Future Treatment of Alzheimer's Disease

Semprini R, Koch G, Belli L, Lorenzo FD, Ragonese M, Manenti G, Sorice GP, Martorana A.

CNS Neurol Disord Drug Targets. 2016;15(6):660-4. doi: 10.2174/1871527315666160518123049.

Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer's Disease

Giubilei F.

CNS Neurol Disord Drug Targets. 2016;15(6):683-9. doi: 10.2174/1871527315666160518122917.

Editorial

Kullmann DM.

Brain. 2016 May;139(Pt 5):1311. doi: 10.1093/brain/aww089.

Alzheimer's Disease and Molecular Chaperones: Current Knowledge and the Future of Chaperonotherapy

Marino Gammazza A, Bavisotto CC, Barone R, de Macario EC, Macario AJ.

Curr Pharm Des. 2016;22(26):4040-9. doi: 10.2174/1381612822666160518141437.

Thalamic pathology and memory loss in early Alzheimer's disease: moving the focus from the medial temporal lobe to Papez circuit

Aggleton JP, Pralus A, Nelson AJ, Hornberger M.

Brain. 2016 Jul;139(Pt 7):1877-90. doi: 10.1093/brain/aww083. Epub 2016 Apr 28.

A possible new role for Aβ in vascular and inflammatory dysfunction in Alzheimer's disease

Zamolodchikov D, Strickland S.

Thromb Res. 2016 May;141 Suppl 2:S59-61. doi: 10.1016/S0049-3848(16)30367-X.

"New Old Pathologies": AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS)

Nelson PT, Trojanowski JQ, Abner EL, Al-Janabi OM, Jicha GA, Schmitt FA, Smith CD, Fardo DW, Wang WX, Kryscio RJ, Neltner JH, Kukull WA, Cykowski MD, Van Eldik LJ, Ighodaro ET.

J Neuropathol Exp Neurol. 2016 Jun;75(6):482-98. doi: 10.1093/jnen/nlw033. Epub 2016 May 21.

A comparative evaluation of treatments with 17β-estradiol and its brain-selective prodrug in a double-transgenic mouse model of Alzheimer's disease

Tschiffely AE, Schuh RA, Prokai-Tatrai K, Prokai L, Ottinger MA.

Horm Behav. 2016 Jul;83:39-44. doi: 10.1016/j.yhbeh.2016.05.009. Epub 2016 May 19.

The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy

Sengupta U, Nilson AN, Kayed R.

EBioMedicine. 2016 Apr;6:42-49. doi: 10.1016/j.ebiom.2016.03.035. Epub 2016 Apr 5.

The news advances on Alzheimer's disease's therapeutics

Sun HQ, Zhang X, Huang WJ, Chen WW.

Eur Rev Med Pharmacol Sci. 2016 May;20(9):1903-10.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias